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Abstract
PEAK1 is a newly described tyrosine kinase and scaffold protein that transmits integrin-mediated extracellular matrix
(ECM) signals to facilitate cell movement and growth. While aberrant expression of PEAK1 has been linked to cancer
progression, its normal physiological role in vertebrate biology is not known. Here we provide evidence that PEAK1
plays a central role in orchestrating new vessel formation in vertebrates. Deletion of the PEAK1 gene in zebrafish, mice,
and human endothelial cells (ECs) induced severe defects in new blood vessel formation due to deficiencies in EC
proliferation, survival, and migration. Gene transcriptional and proteomic analyses of PEAK1-deficient ECs revealed a
significant loss of vascular endothelial growth factor receptor 2 (VEGFR2) mRNA and protein expression, as well as
downstream signaling to its effectors, ERK, Akt, and Src kinase. PEAK1 regulates VEGFR2 expression by binding to and
increasing the protein stability of the transcription factor GATA-binding protein 2 (GATA2), which controls VEGFR2
transcription. Importantly, PEAK1-GATA2-dependent VEGFR2 expression is mediated by EC adhesion to the ECM and is
required for breast cancer-induced new vessel formation in mice. Also, elevated expression of PEAK1 and VEGFR2
mRNA are highly correlated in many human cancers including breast cancer. Together, our findings reveal a novel
PEAK1-GATA2-VEGFR2 signaling axis that integrates cell adhesion and growth factor cues from the extracellular
environment necessary for new vessel formation during vertebrate development and cancer.
Introduction
New blood vessel formation from the pre-existing vas-
culature, termed angiogenesis, is essential for proper
development in all vertebrates, and its deregulation
contributes to many different diseases including cancer1.
It is now established that the angiogenic process in nor-
mal and diseased tissues is primarily driven by VEGFA
and its receptor VEGFR2, which transmit signaling cas-
cades that direct endothelial cell (EC) spouting, migration,
and proliferation, as well as cytoskeletal changes needed
for proper tube formation2. In addition to VEGFA-
VEGFR2 signaling, new blood vessel construction
requires ECs to adhere to, remodel, and invade through
dense arrays of complex extracellular matrix (ECM)
proteins present in the basement membrane and tissue
parenchyma3. ECM proteins are particularly important in
angiogenesis because they transmit crucial positional and
mechanical signals to the interior of the cell which
orchestrate EC movement, growth, differentiation, and
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survival3. Thus, it is crucial that ECs can sense and
respond to cues from both ECM proteins as well as
growth factors present in the extracellular environment.
In fact, pharmacological and therapeutic targeting of
VEGFR2 or ECM-mediated focal adhesion signaling
potently inhibits vascular formation in vitro and blocks
angiogenesis in preclinical animal models3–5. Therefore, it
is important to understand in detail how ECM proteins
and VEGFR2 signaling coordinately regulate EC biology
under normal and diseased states.
Pseudopodium-enriched atypical tyrosine kinase 1
(PEAK1, Sgk269) is a newly discovered non-receptor
tyrosine kinase ubiquitously expressed in all tissues,
highly conserved in vertebrates, and is deregulated in
many different cancers6. PEAK1 regulates focal adhesion
dynamics and integrin signaling to the actin cytoskeleton
in breast and pancreatic cancer cells7. Biochemically,
PEAK1 interacts with Src, Shc1, Crk, and Grb2 adaptor
proteins in the cytoplasm to convey signals from mem-
brane receptor tyrosine kinases such as EGFR and ErbB2,
which mediate cancer cell migration and proliferation7–10.
Recently, PEAK1 was shown to interact with and regulate
YAP1/TAZ in pancreatic cancer cells11. YAP1/TAZ is a
central cytoskeletal tension sensor and transcriptional co-
activator that controls cell proliferation, shape, and size in
response to biomechanical signals from the ECM12. These
accumulating data indicate that PEAK1 serves as a scaf-
fold to integrate and transmit multiple signals from the
extracellular environment to the interior of cancer cells.
However, to fully understand PEAK1′s role in cancer it is
necessary to understand its normal physiological role in
the body, which is not yet known. Here we investigate the
normal physiological function of PEAK1 in PEAK1
knockout mice, zebrafish, and human ECs. PEAK1 was
found to regulate vertebrate angiogenesis by modulating
GATA2-mediated VEGFR2 transcription and down-
stream signaling in response to ECM signaling. In addi-
tion, interrogation of cancer databases revealed that
elevated levels of PEAK1 and VEGFR2 mRNA are highly
correlated in many human cancers, suggesting that the
regulation of the PEAK1-VEGFR2 axis contributes to this
disease.
Results
PEAK1 is highly conserved in vertebrates and is important
for angiogenesis
Zebrafish is a well-established model organism to study
vertebrate development, genetics, and angiogenesis. Zeb-
rafish embryos are transparent, develop rapidly ex vivo,
and are readily amenable to genetic manipulation and
microscopy imaging, and thus are an ideal model to study
the physiological role of PEAK1 in vertebrates. The zeb-
rafish peak1 gene (Gene ID: 565111) encodes a protein
with 1695 amino acids (aa), which is slightly shorter than
the proteins encoded by the mouse Peak1 gene (Gene ID:
244895, 1735 aa) and the human PEAK1 gene (Gene ID:
79834, 1746 aa). The percentage of sequence identity of
PEAK1 proteins of Homo sapiens, Mus musculus, and
Danio rerio is 44.5%, while the percentage of consensus
positions is 92.0% (Supplementary Fig. S1a). Moreover,
PEAK1′s protein interaction domains and phosphoryla-
tion sites are highly conserved in vertebrates, which
include the actin binding domain (aa 339–727), the
putative tyrosine kinase domain (aa 1330–1664), and the
Src family kinase consensus phosphorylation sites (aa
Y635 and Y665) (Supplementary Fig. S1b). Thus, PEAK1
is well conserved among vertebrates and likely to play an
important role in vertebrate physiology.
To determine the role of peak1 in early zebrafish
development, we used two different splice-blocking
morpholinos (MOs, SP1MO, and SP2MO) to knock-
down peak1 expression in fertilized embryos (Supple-
mentary Fig. S2a). The knockdown efficiency of MOs was
confirmed by quantitative real-time RT-PCR (qPCR) and
western blotting (WB) (Supplementary Fig. S2d and e).
The peak1 knockdown embryos developed normally for
the first 24 h-post-fertilization (hpf) and displayed normal
gastrulation, somite, and body formation. However, by 2
days-post-fertilization (dpf) peak1-depleted deficient
embryos showed prominent vascular defects character-
ized by pericardial edema and blood accumulation in the
anterior aorta and tail region (Fig. 1a, b). These animals
survived for 10–12 dpf before succumbing to vascular
problems. The primitive brain, notochord, somites, and
overall body pattern were grossly normal during early
development. These findings indicate that peak1 may play
a role in vasculature development, but is largely dis-
pensable for other morphological development.
To further characterize the observed vascular defects in
peak1-knockdown embryos, we utilized Tg(fli1:egfp)y1
transgenic zebrafish, which express GFP throughout their
vascular system making them readily amenable to high
resolution intravital confocal microscopy13. This animal
model has been widely used to characterize vessel for-
mation and dissect the genetic programs that regulate
vertebrate angiogenesis. Interestingly, imaging of the
developing vasculature in peak1-depleted embryos at 32
hpf revealed major defects in extension of intersegmental
vessels (ISV) from the dorsal aorta (DA) or posterior
cardinal vein (PCV) (Fig. 1c, d). Endothelial tip cells and
stalks initially sprouted from DA or PCV, but showed
stunted extension with numerous disorganized cellular
projections, which failed to connect to the dorsal long-
itudinal anastomotic vessels (DLAV). In addition, the
subintestinal vessels (SIV) did not extend properly from
the duct of Cuvier, preventing vascular plexus formation
in the abdominal region (Fig.1e, f). Importantly, injection
of peak1 mRNA into developing embryos rescued the ISV
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vascular defects induced by SP1MO, reducing the possi-
bility of off-target effects (Fig. 1g). These findings indicate
that peak1 is necessary for proper vascular development
in zebrafish embryos.
To independently confirm the peak1 morpholino-
induced vascular defects, we designed a pair of Tran-
scription Activator-like Effector Nucleases (TALEN) for
peak1 gene using a TALEN scaffold toolbox optimized for
zebrafish14. The designed targeting site locates at exon 1
of the zebrafish peak1 gene (Supplementary Fig. S2b).
TALEN mRNAs were injected into wildtype embryos at
the one-cell stage and individual F0 founder embryos
were genotyped at 2dpf. The genotyping results suggest
the somatic targeting efficiency ranges from ~10 to ~60%
(Supplementary Fig. S2f). Previous studies suggest high
targeting efficiency in F0 founder embryos can result in
biallelic gene targeting in some somatic cells15. Interest-
ingly, we did observe that ~ 30% of peak1 TALEN-
injected embryos showed similar blood circulation defects
as the peak1 morphants (Supplementary Fig. S2g and h).
Next, we injected peak1 TALEN mRNAs into Tg(fli1:
egfp)y1 embryos. Notably, while about 40% of the embryos
injected with TALEN mRNAs targeting both arms
(TALEN R+ L) showed mosaic ISV defects, injection of
same amount of single arm TALEN mRNA (TALEN R or
TALEN L) had no effect (Fig. 1h and Supplementary Fig.
S2i). These results suggest the mosaic vascular defects
caused by peak1 TALEN injection may be due to genetic
ablation of zebrafish peak1 gene in the somatic cells.
We next outcrossed the F0 founder fish of peak1
TALEN to generate F1 progeny. Sequencing and geno-
typing of these animals revealed various point and fra-
meshift mutations in the peak1 gene (Supplementary Fig.
S2j). We focused on the F1 line #2–6, which has a 2 base
pair frameshift in peak1 coding region. The line # 2–6
zebrafish were outcrossed for two generations, followed
by backcrossing to obtain homozygous mutants (peak1Δ2/
Δ2). Interestingly, although homozygous peak1Δ2/ Δ2 is a
null mutant as embryos do not express peak1 protein
(Supplementary Fig. S2k), these animals do not display
vascular defects and survive to become fertile adults (data
not shown). The discrepancy in the phenotypic differ-
ences between TALEN-induced genetic peak1 mutations
and splicing-MO-induced peak1 depletion have two
possible sources. First, the vasculature defects induced by
the peak1 MO could be due to off-target effects, but this
was considered unlikely because we obtained similar
phenotypes with two independent MOs, and the addition
of peak1 mRNA rescued the vascular defects in these
animals. Second, it is possible that genetic compensation
occurred subsequent to the introduction of deleterious
peak1 mutations induced by TALENs, and such com-
pensations are not uncommon in genetic deleterious
animal models16. To investigate possible compensation
due to deleterious peak1 null mutations, we used a similar
strategy described by Rossi et al.16. We reasoned that if
the peak1 MO specifically targeted zebrafish peak1 gene
and genetic compensation occurred in peak1 null mutants
(peak1Δ2/ Δ2), the peak1 MO should not cause vascular
defects in peak1 null mutant. To test this hypothesis, the
progeny from incrosses of peak1Δ2/+ heterozygotes were
injected with SP1 MO at the one-cell stage. At 72 hpf, two
groups of embryos were separated and individually gen-
otyped. Group I included only embryos exhibiting vas-
cular defects (i.e., ISV defects, reduced circulation loop
and/or pericardial edema, means embryos are sensitive to
peak1 MO), whereas Group II embryos were randomly
selected (control group with theoretical Mendelian dis-
tribution of genotypes). Based on genotyping, there were
much fewer peak1Δ2/ Δ2 null mutants in group I than the
control group II, suggesting peak1Δ2/ Δ2 mutants are
indeed much less sensitive to the peak1 MO (Fig. 1i).
(see figure on previous page)
Fig. 1 peak1 is required for vascular development in zebrafish embryos. a Bright-field images of pericardial edema (upper panel, arrowhead)
and blood accumulation in the anterior aorta as well as in the tail region (arrows) of peak1 morpholino (MO) knockdown embryos (SP1MO). Pictures
were taken at 2 days-post-fertilization (2dpf). Also see Supplementary Fig.S2c. b Bar graph shows the percentage of animals with vascular defects
caused by control (Ctrl MO) or two different peak1 specific morpholinos SP1MO and SP2MO. Mean ± SEM; n= 30. c Confocal images at indicated
time points of vasculature formation of Tg(fli1:egfp)y1 zebrafish embryos treated as in (a). ISVs= intersegmental vessels. DLAVs= dorsal longitudinal
anastomotic vessels. DA= dorsal aorta. PCV= posterior cardinal vein. hpf= hours-post-fertilization. Arrows point to disorganized endothelial sprouts
and vessel structures. d Bar graph depicts the average ISV length at 32 hpf of MO-treated embryos. Mean ± SEM; n= 50. e Confocal images of
subintestinal vessels (SIVs, dashed line circled region) were captured at 3dpf from embryos treated as in (c). Arrows show SIV defects. f Bar graph
shows the cumulative length of SIVs per embryo from embryos treated as in (e); Mean ± SEM; n= 10. g Bar graph represents the average ISV length
at 32hpf of embryos treated as in (c) and co-treated with peak1 mRNA or a nonspecific control mRNA (Ctrl mRNA). Mean ± SEM; n= 50. h Bar graph
shows the percentage of Tg(fli1:egfp)y1embryos with mosaic disrupted ISV defects after treatment of peak1 specific transcription activator-like effector
nuclease (TALEN) mRNAs. TALEN R= right arm (120 pg); TALEN L= left arm (120 pg); TALEN R+ L= both arms (60 pg each); Mean ± SEM; n= 90. i
Embryos from incrossed heterozygous peak1 Δ2/ + zebrafish were injected with SP1MO at one-cell stage, subsequently selected at 72 hpf for the
vascular defects (Sensitive to SP1MO) or randomly selected and all genotyped individually. Bar graph represents percentage of homozygous peak1Δ2/
Δ2 in each group. Mean ± SEM; n= 90. All the data are representative of at least three independent experiments. ***, P < 0.001; **, P < 0.01; N.S., not
significant; in (b, d), vs. Ctrl MO; in (h), vs. TALEN R+ L. Scale bar= 50 μm
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According to the newly published “Guidelines for mor-
pholino use in zebrafish”17, we conclude that peak1 MOs
specifically target zebrafish peak1 gene and homozygous
peak1Δ2/ Δ2 zebrafish are viable and lack vascular defects
due to genetic compensation. Taken together, our results
indicate peak1 is required for proper vascular formation
in zebrafish embryos.
peak1 cell-autonomously regulates vegfa-induced EC
migration and proliferation during vessel formation in
zebrafish
We next investigated how peak1 regulates zebrafish ISV
formation in vivo. Previous work using time-lapse ima-
ging of vessel development in zebrafish embryos shows
that ISV formation requires cell sprouting from DA or
PCV, tip cell migration, and cell proliferation of a defined
number of ECs13. To determine how peak1 depletion
impacts these different processes, we performed time-
lapse intravital imaging of transgenic Tg(fli1:nls-egfp)
zebrafish embryos that express GFP in the nucleus of all
ECs with or without peak1 depletion. Interestingly, while
endothelial tip cells can sprout from the DA in peak1-
deficient animals, they displayed severely impaired
migration around the notochord compared to control
animals (Fig. 2a, Supplementary Movie S1 and S2). Fur-
thermore, peak1-depleted animals showed a significant
reduction of the total number of ECs per each ISV
compared to controls (Fig. 2a, b). These findings suggest
that peak1 controls EC migration and proliferation during
zebrafish ISV formation in vivo.
To determine if peak1 functions cell-autonomously in
the ECs during ISV formation, cells from Tg(fli1:egfp)y1
embryos were isolated and transplanted into recipient
wild type host embryos at early sphere stage (see sche-
matic Supplementary Fig. S3). Donor cells from control
animals injected into host embryos with peak1 depletion
formed normal ISVs, whereas peak1-depleted donor cells
injected into control embryos formed disorganized and
stunted ISVs (Fig. 2c, d). Altogether, these findings indi-
cate that peak1 regulates EC migration and proliferation
during zebrafish ISV development in a cell-autonomous
manner.
The vascular defects observed in the peak1-depleted
zebrafish embryos were similar to the cardiac edema and
blood pooling defects described in zebrafish models of
perturbed vegfa/vegfr2 signaling18. Importantly, vegfa/
vegfr2 signaling plays a prominent role in the develop-
ment of SIV and ISV vessels in zebrafish5. Therefore, we
investigated a possible role for peak1 in regulating vegfa/
vegfr2 signaling and angiogenesis. Tg(fli1:egfp)y1 embryos
were co-injected with suboptimal doses of MOs to peak1
and/or vegfa and then monitored for vessel formation.
Animals injected with suboptimal doses of either peak1 or
vegfa MO alone showed only minor vessel defects,
whereas animals co-injected with both MOs showed
dramatic loss of ISVs (Fig. 2e, f). These findings suggest
that peak1 and vegfa may act synergistically to mediate
ISV formation.
PEAK1 regulates VEGFA-induced human EC migration,
proliferation, and survival as well as vessel morphogenesis
in vitro
To further explore the potential role of PEAK1 in
VEGFA-mediated EC functions, we first used a well-
established 3D bead sprouting angiogenesis assay with
primary human umbilical vein endothelial cells
(HUVECs)19. This model provides a defined ECM
microenvironment and growth factor stimuli for the ECs,
and recapitulates all the key stages of angiogenesis
including EC sprouting, ECM invasion, migration, pro-
liferation, lumen formation, and microcapillary branching
and anastomosis. HUVECs were depleted of PEAK1 by
siRNA treatment (Supplementary Fig. S4a) and allowed to
attach to Cytodex beads, which were then imbedded in
fibrin gels and overlaid with fibroblasts. Cell cultures were
then treated with or without recombinant human VEGFA
(VEGF-165) to induce sprouting and vessel formation.
PEAK1-depleted HUVECs showed significantly reduced
VEGFA-induced vessel sprouting compared to control
cells (Fig. 3a, b). In addition, PEAK1 depletion inhibited
VEGFA-induced tube formation in a standard EC tube-
forming assay using Matrigel-coated dishes (Fig. 3c, d).
These results suggest PEAK1 cell-autonomously regulates
VEGFA-induced morphogenesis of ECs in vitro.
To determine how PEAK1 facilitates vessel formation
in vitro, we monitored the real-time EC migration and
proliferation with the xCELLigence biosensor technology
under PEAK1-depleted conditions. The results suggest
PEAK1 depletion strongly inhibited VEGFA-induced cell
migration and proliferation in both HUVECs and primary
human cardiac microvascular endothelial cells (HMEVCs)
(Fig. 3e–j and Supplementary Fig. S4c and d). Consistent
with these findings, peak1 knockdown in Tg(fli1:nls-egfp)
zebrafish embryos inhibited EC migration and prolifera-
tion in vivo (Fig. 2a, b). Importantly, the inability of
PEAK1-depleted cells to migrate and proliferate in vitro
was not due to their inability to attach to the collagen-
coated plates (Supplementary Fig. S4b). In addition,
VEGFA-induced cell survival was significantly inhibited in
PEAK1-depleted HUVECs (Fig. 3k). Importantly, treat-
ment with cell permeable zVAD-FMK, a pan caspase
inhibitor, rescued the apoptotic response in PEAK1-
depleted HUVECs, indicating that cell death was due to
caspase-mediated apoptosis (Fig. 3k). Altogether, these
results indicate that PEAK1 regulates VEGFA-induced EC
vessel morphogenesis in vitro by mediating EC growth,
survival and migration.
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PEAK1 regulates VEGFR2 protein expression as well as
downstream signaling in human ECs
To gain a mechanistic understanding of how PEAK1
alters EC functions, we profiled the protein networks
altered in PEAK1-depleted HUVECs. For these studies,
we used quantitative multiplexed proteomics and isobaric
labeling with tandem mass tags (TMT)20. This technology
facilitated simultaneous and quantitative analyses of three
biological replicates from both PEAK1-depleted and mock
treated control HUVECs. Only proteins with more than
1.5-fold differences in the control samples relative to the
PEAK1-depleted samples with a P value < 0.05 were
considered significantly changed by PEAK1-depletion. A
total of 5565 proteins were identified across all groups
(Fig. 4a; Supplementary Table S4). PEAK1-depleted
HUVECs showed 63 down-regulated and 103 up-
Fig. 2 peak1 is required for endothelial cell (EC) proliferation and migration in zebrafish early development. a Confocal images of labeled ISV
ECs at 28hpf of Tg(fli:nls-egfp) embryos treated with MOs. Also see Video S1 and S2. Arrows point to tip cells sprouting from DA. Dashed line=
notochord (NC). b Bar graph represents the average number of ECs per ISV. Mean ± SEM; n= 30. c Endothelial precursor cells were isolated from
sphere stage Tg(fli1:egfp)y1 embryos (donor) and transplanted into same stage wild type AB host embryos (host). Either donor or host embryos were
treated with indicated MOs at one-cell stage. ISV formation from engrafted GFP ECs were imaged using confocal microscopy at 32hpf. d Bar graph
shows the average length of GFP labeled ISVs from embryos treated as in (c). Mean ± SEM; n= 10. All data are representative of at least three
independent experiments. e Confocal images of ISVs of Tg(fli1:egfp)y1 embryos treated with sup-optimal amount of Ctrl MO, SP1MO, VEGF MO or
indicated combination. Arrows show stunted ISVs. f Bar graph shows the average length of ISVs from embryos treated as in (e). Mean ± SEM; n= 30.
***, P < 0.001; N.S., not significant. Scale bar= 30 μm
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Fig. 3 (See legend on next page.)
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regulated proteins (Supplementary Table S5). The func-
tional relevance of proteins altered by PEAK1 loss was
classified using Gene Ontology (GO) and network ana-
lysis. Of the 63 down-regulated proteins, 13 proteins have
known or predicted functions in vasculature development
or angiogenesis, and the majority are proangiogenic pro-
teins including Jagged1 (JAG1), Matrix metalloproteinase-
1 (MMP1), Intercellular Adhesion Molecule 1 (ICAM1)
and VEGFR2 (Fig. 4b, c).
The VEGFR2 receptor was of major interest because it
was ~2.5 fold downregulated in PEAK1-depleted cells
(Fig. 4b), and it is the primary receptor tyrosine kinase
that mediates VEGFA-induced angiogenesis2. Western
blotting confirmed the specific downregulation of
VEGFR2 protein, but not VEGFR1, in PEAK1-depleted
HUVECs (Fig. 5a) and HMVECs (Supplementary Fig. S5).
VEGFA ligand activates VEGFR2 and critical downstream
signals including MEK/ERK, SRC, and AKT, which can be
detected with phosphospecific antibodies that report the
activated forms of these proteins5. VEGFR2 activation
itself and phosphorylation of MEK/ERK, SRC, and AKT
were all inhibited in PEAK1-depleted HUVECs compared
to control cells upon VEGFA stimulation (Fig. 5a). Similar
findings were observed in PEAK1-depleted HMVECs
(Supplementary Fig. S5). Importantly, re-expression of
GFP-tagged PEAK1 in PEAK1-depleted HUVECs
restored VEGFR2 expression (Fig. 5b). Altogether, these
findings indicated that VEGFR2 expression and its major
downstream signals were severely disrupted in PEAK1-
depleted human ECs, which could result in impaired EC
proliferation, migration, and survival in response to
VEGFA stimuli (Fig. 3).
PEAK1 regulates VEGFR2 gene transcription through
GATA2
The expression of VEGFR2 protein in ECs is tightly
regulated by proteasome- and/or lysosome-mediated
receptor degradation5. However, the protein degradation
rate of VEGFR2 under the protein synthesis inhibitor
Cycloheximide (CHX) treatment was not changed by
PEAK1-depletion (Fig. 5c, d). Moreover, neither the
proteasome inhibitor MG-132 nor the lysosomal inhibitor
Chloroquine (CHQ) rescued the reduced VEGFR2 protein
expression caused by PEAK1-depletion, indicating that
PEAK1 does not regulate protein degradation of VEGFR2
(Fig. 5e). Since PEAK1-depletion does not alter VEGFR2
protein stability, we investigated whether PEAK1 reg-
ulates VEGFR2 mRNA expression. For these studies, we
plated HUVEC cells on collagen I-coated plates since
ECM proteins have been reported to upregulate VEGFR2
expression and PEAK1 is a focal adhesion protein that
transmits integrin-ECM signals in cancer cells7, 9, 21.
PEAK1 depletion strongly down-regulated VEGFR2, but
not VEGFR1 mRNA levels in both HUVECs and
HMVECs (Fig. 6a). Importantly, re-expression of PEAK1
in PEAK1-depleted cells rescued the loss of VEGFR2
mRNA (Fig. 6b) and protein (Fig. 5b). Interestingly,
HUVECs adhesion to the ECM protein collagen I or
fibronectin dramatically increased VEGFR2 mRNA
expression, and PEAK1-depletion completely abolished
this effect (Fig. 6c). Furthermore, the transcriptional
activity of the VEGFR2 promoter was also significantly
impaired under these conditions (Fig. 6d). These findings
indicate PEAK1 is required for ECM-regulated VEGFR2
gene transcription in ECs.
Mechanical cues induced by EC adhesion to the ECM
regulates nuclear localization of GATA2 and GTF2I to
regulate VEGFR2 transcription in p190RhoGAP-
dependent manner21. GATA2 is a transcriptional acti-
vator while GTF2I is a transcriptional repressor of
VEGFR2 transcription21. Surprisingly, the nuclear-to-
cytoplasmic ratios of GATA2 or GTF2I were not altered
by PEAK1-depletion in HUVECs attached to a collagen
matrix (Fig. 6e and Supplementary Fig. S6a). However,
GATA2, but not GTF2I, antibody staining was noticeably
reduced in PEAK1-depleted cells compared to control
cells, suggesting the GATA2 protein level is specifically
down-regulated in these cells. Indeed, GATA2 and
(see figure on previous page)
Fig. 3 PEAK1 is required for Vascular Endothelial Growth Factor A (VEGFA)-induced proliferation, migration and morphogenesis of human
ECs in vitro. a Phase-contrast images of fibrin gel sprouting assay with Human Umbilical Vein Endothelial Cells (HUVECs) transfected with control
(siCtrl) or PEAK1 (siPEAK1-1) siRNA and treated with (+VEGF) or without VEGF (-VEGF). Arrowheads show vessel sprouts radiating from the bead
surface. b Bar graph represents the cumulative length of sprouts per bead. Mean ± SEM; n= 10. c Phase-contrast images of Matrigel tube-forming
assay with HUVECs treated with siRNAs in the presence or absence of VEGF. Arrows show vascular tubes. (d) Bar graph represents cumulative length
of vascular tubes (per mm2) formed as in (c). Mean ± SEM; n= 5. Real-time cell migration (e, f, i) or proliferation (g, h, j) kinetics were measured by
xCELLigence electrical impedance system of HUVECs (e–h) or Human Cardiac Microvascular Endothelial Cells (HMVECs, i, j) treated with indicated
siRNAs. The chambers were coated with collagen I. Bar graph represents the slopes of the migration curves (f, i, from 2 to 12 h) or proliferation curves
(h, j, from 4 to 72 h) of HUVECs and HMVECs. CI= Cell Index; Mean ± SEM of quadruplicate wells. (k) HUVECs were transfected with indicated siRNA,
treated with or without VEGF and co-treated with or without zVAD, a pan-caspase inhibitor. Apoptosis was then measured by FACS with staining of
7-AAD and FITC-Annexin-V. Bar graph represents relative apoptotic cell ratio normalized with (–VEGF+ siCtrl) group. Mean ± SEM; n= 3. All data are
representative of at least three independent experiments. ***P < 0.001; **P < 0.01; *P < 0.05; N.S., not significant; (f, h, i, j), vs. siCtrl+ VEGF group. Scale
bar= 10 μm
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Fig. 4 PEAK1 regulates the expression of multiple pro-angiogenic factors in human ECs. a Volcano plot for quantitative multiplexed
proteomics revealed 5565 proteins across all HUVECs samples treated with siCtrl or siPEAK1 (Also see Supplementary Table S4). A total of 103 proteins
were significantly up-regulated while 63 proteins were significantly down-regulated in the siPEAK1 samples relative to the siCtrl samples, (n= 3, p <
0.05, fold-change ≥1.5, dark dots, also see Supplementary Table S5). b Bar graph represents the normalized summed S/N value of VEGFR2 (Left) or
PEAK1 (Right) protein level identified by multiplexed proteomics. Mean ± SEM; n= 3; **P < 0.003; *P < 0.02. c Protein network analysis using
STRING10.0 of downregulated proteins in HUVECs by PEAK1 depletion from quantitative multiplex proteomic analysis. Proteins with known or
predicted functions in vascular development or angiogenesis are highlighted (Red ball)
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VEGFR2, but not GTF2I or p190RhoGAP proteins, were
reduced in PEAK1-depleted HUVECs attached to col-
lagen or fibronectin coated plates (Fig. 6f, g). It is also
notable that VEGFR2 and GATA2 protein expression
were specifically up-regulated in response to HUVEC
adhesion to collagen and fibronectin, whereas GTF2I and
p190RhoGAP protein expression did not change (Fig. 6f,
g). These findings indicate that PEAK1 uniquely regulates
VEGFR2 and GATA2 protein expression in response to
EC adhesion to the ECM.
To determine if PEAK1 regulates VEGFR2 transcription
through GATA2, we re-expressed GATA2 in PEAK1-
depleted HUVECs. GATA2 restored VEGFR2 mRNA and
protein expression as well as its downstream signals in
human ECs (Fig. 7a, b). Also, because gata2a plays a
crucial role in zebrafish vascular development by reg-
ulating vegfr2 expression22, 23, we tested the ability of
gata2a mRNA to rescue the peak1-mediated vascular
defects in zebrafish. Co-injection of gata2a mRNA in
peak1 knockdown zebrafish embryos rescued ISV for-
mation and vegfr2 mRNA expression (Fig. 7c, d). More-
over, PEAK1 co-immunoprecipitated with GATA2 in an
ECM-dependent manner (Fig. 7f, g). Altogether, these
findings indicate that PEAK1 associates with GATA2 and
that a PEAK1-GATA2 signaling complex works collec-
tively to regulate VEGFR2 mRNA expression in response
to ECM proteins.
Because GATA2 protein, but not mRNA levels, were
significantly reduced in PEAK1-depleted ECs (Fig. 6e–g,
Supplementary Fig. S6b), and GATA2 protein expression
Fig. 5 PEAK1 regulates VEGFR2 protein expression and VEGFA-VEGFR2 signaling in human ECs. a Western blots (WB) with indicated
antibodies of HUVECs treated with siRNAs and stimulated with or without VEGF. In all western blots, α-tubulin and GAPDH served as loading controls.
b WB of HUVECs treated with siRNAs and transfected with or without non-targeted GFP-PEAK1 or control GFP only. c WB of HUVECs treated with
siRNAs and with or without protein synthesis inhibitor cycloheximide (CHX) for indicated times. d Graph shows relative protein amount of VEGFR2 vs.
α-Tubulin of HUVECs treated as in (c); Mean ± SEM; n= 3. e WB of HUVECs treated with siRNAs and with or without proteasome inhibitor MG-132
(left) or lysosome inhibitor chloroquine (CHQ, Right). All data are representative of at least three independent experiments
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is regulated by ubiquitination24, 25, we determined if
PEAK1 regulates GATA2 ubiquitination and protein
stability. The proteasome inhibitor MG-132 restored the
reduced GATA2 protein level in PEAK1-depleted
HUVECs (Fig. 7e). Importantly, ECM adhesion inhibited
GATA2 ubiquitination and PEAK1 depletion abolished
this effect completely (Fig. 7h, Supplementary Fig. S6c).
These findings indicate that EC-ECM adhesion promotes
the interaction between PEAK1 and GATA2, and reg-
ulates GATA2 protein ubiquitination and stability.
Peak1 regulates Vegfa-induced angiogenesis in mice
The mouse intraretinal vasculature develops postnatally
in a tightly regulated temporal and spatial pattern that can
be readily observed by microscopy. In C57BL/6 mice, the
superficial vascular plexus forms during the first week
after birth by radial outgrowth of vessels from the optic
nerve into the periphery, reaching the retinal edges at
approximately postnatal day 8 (P8). From P7 onward, the
superficial capillaries sprout vertically to form first the
deep and then the intermediate vascular plexus. This
process is well-known to be ECM, Vegfa/Vegfr2 and
Gata2 dependent21. Therefore, we wanted to determine
the functional relevance of Peak1 in mouse angiogenesis
and retinal plexus formation. To facilitate these studies,
we developed Peak1flox/flox and Peak1−/− knockout mouse
in the C57BL/6 background by targeted deletion of exon 4
of the Peak1 gene. Genotyping, qPCR, and western blot-
ting of isolated tissues demonstrated that Peak1−/− is a
null mutant (Supplementary Fig. S7a-d and S8b). Inter-
estingly, close examination of developing P7 neonatal
retinas from Peak1−/− mice revealed significantly reduced
outgrowth of the superficial vessel plexus when compared
to matched littermates with Peak1 gene (Peak1+/−, and
Peak1+/+) (Fig. 8a). Also, the numbers of branch points of
the retinal vasculature in Peak1 null mutants were sig-
nificantly reduced (Fig. 8b). These findings indicate that
Peak1 plays an important regulatory role in the angio-
genesis of developing mouse retina. These findings are
consistent with the findings from human ECs in vitro and
developing zebrafish embryos in vivo (Figs. 1 and 5). It
should be noted that Peak1−/− animals bred normally at
expected Mendelian ratios, had normal complete blood
counts (Supplementary Table S6), and did not show gross
developmental or obvious health abnormalities, except for
an increased incidence of malocclusions (3.49% in
Peak1−/−, n= 229 vs. 0.00% in Peak+/+, n= 187; while
0.046% in wildtype C57BL/6 mice reported by Jackson
Labs), suggesting the phenotype of Peak1−/− animals are
very specific. It is also notable that the vascular plexus in
adult retinas from Peak1−/− and Peak1+/+ mice appeared
fully developed without morphological defects (Supple-
mentary Fig. S8a). This suggests that the loss of Peak1
delays retinal vessel formation during early development,
but at later stages the animal can compensate for the loss
of Peak1 to form a complete and functional retinal plexus.
While it seems Peak1 is primarily involved in early
vascular development of zebrafish and mouse, we inves-
tigated whether Peak1 also plays a role in vascular
remodeling processes in adult tissues under certain con-
ditions, such as Vegfa-induced vessel outgrowth in dis-
sected tissues from fully developed adult mice. The
ex vivo aortic ring assay is a reliable and reproducible
angiogenesis assay to study specific growth factor-induced
angiogenesis of mouse tissues in a defined ECM micro-
environment26. Dissected aortic tissues were cultured in
Reduced Growth Factor Basement Membrane Matrix and
allowed to spontaneously generate outgrowths of
branching microvessels in response to VEGFA treatment,
which can be easily monitored and quantified by direct
microscopic observation. In this model, aortas from
Peak1−/− and Peak1+/- mice showed strikingly reduced de
novo cumulative vessel formation and reduced number of
new vessel sprouts compared to aortas from Peak1+/+
animals (Fig. 8c, Supplementary Fig. S8c). In addition, the
average sprout length was dramatically reduced in
Peak1−/− animals compared to Peak1+/- and Peak1+/+
mice (Supplementary Fig. S8d). We also isolated aortas
from Peak1flox/flox animals and then treated them with an
adenovirus either encoding GFP (CMV-GFP) or Cre
(see figure on previous page)
Fig. 6 PEAK1 mediates extracellular matrix (ECM)-regulated VEGFR2 mRNA transcription in human ECs. a–c Bar graphs represent relative
mRNA levels vs. HPRT1 measured by quantitative RT-PCR (qPCR) and normalized against siCtrl. Mean ± SEM; n= 3. a, b Cells were cultured on
collagen I-coated plates. a HUVECs or HMVECs were treated with siRNAs. P value, vs. siCtrl in each target mRNA. b HUVECs were treated with siRNAs
and transfected with or without non-targeted GFP-PEAK1 (Rescue) or GFP only; c HUVECs were attached to plastic dishes coated with either collagen
I (Colla), fibronectin (Fibro), or left uncoated (Un) and treated with different siRNAs. d HUVECs treated as in (c) were transfected with the plasmid of
luciferase driven by VEGFR2 promoter. Bar graph represents relative luciferase activity measured by illuminometer and normalized against siCtrl+
Uncoated group. Mean ± SEM; n= 4. e Confocal images of siCtrl and siPEAK1 treated HUVECs stained with GATA2 or GTF2I antibodies (green) along
with DAPI, as a nuclear stain (blue). Cells were cultured on collagen I coated coverglass. Scale bar= 10 μm. f WB of HUVECs attached to different
coated plates and treated with siRNAs. g Bar graph shows relative protein level vs. α-tubulin from HUVECs treated as in (f). Relative densitometry from
three independent WB were analyzed by Image J. Mean ± SEM; n= 3. All data are representative of at least three independent experiments. ***P <
0.001; **P < 0.01; *P < 0.05; N.S., not significant
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Fig. 7 PEAK1 regulates VEGFR2 transcription through GATA2. a WB of HUVECs treated with siRNAs, transfected or not transfected with a plasmid
encoding GATA2, and stimulated with or without VEGF for 10 mins. Cells were cultured on collagen I coated plates. b Bar graph represents relative
mRNA levels vs. HPRT1 by qPCR analysis of HUVECs treated as in (a). c Confocal images of ISVs at 32 hpf of Tg(fli1:egfp)y1embryos with co-injection of
gata2a mRNA or control mRNA and indicated MOs. Arrows point to stunted and disorganized endothelial sprouts. Scale bar= 50 μm. d Left bar
graph represents the average ISV length of embryos treated as in (c). Mean ± SEM; n= 50. Right bar graph represents relative mRNA levels vs.
zebrafish actb1 from the embryos treated as in (c) by qPCR analysis. Mean ± SEM; n= 3. HUVECs were cultured on collagen I-coated plates in (e) and
(f). e WB of HUVECs transfected with siRNAs and treated with proteasome inhibitor MG-132. f, g Co-immunoprecipitated (IP) proteins from HUVECs
with anti-GATA2 agarose were analyzed by WB for indicated proteins. In g, HUVECs were attached to plastic dishes with indicated coating. To
compensate the protein level of GATA2 in Un group, the input was 1.8 folds compared to Fibro and Colla. h HUVECs were attached to plastic dishes
with indicated coating and treated with different siRNAs. ECs were then treated with MG-132 for 6 h. Ubiquitination of IPed GATA2 protein was
analyzed by WB. All data are representative of at least three independent experiments. ***P < 0.001; **P < 0.01; *P < 0.05; N.S. not significant
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recombinase (CMV-Cre) to induce de novo Peak1-dele-
tion. The CMV-Cre treated aortas showed strongly
reduced microvessel formation in response to VEGFA
compared to CMV-GFP treated aortas, which was
associated with reduced VEGFR2, but not VEGFR1
mRNA expression (Fig. 8d). Altogether, our findings
suggest that Peak1 regulates VEGFA-induced
Fig. 8 Peak1 is required for VEGFA-induced angiogenesis in mouse tissues. a Anti-CD31 immunofluorescence labeling of the developing
vascular plexus of P7 neonatal retinas isolated from heterozygous (Peak1+/−) or homozygous (Peak1−/−) mutant mice. Scale bar= 500 μm. Bar graph
represents the mean area of vascularized retinal tissue in Peak1+/+, Peak1+/−, or Peak1−/− mice; Mean ± SEM; n= 6 in Peak1+/+; n= 10 in Peak1+/−;
n= 6 in Peak1−/−. b Vasculature branch points of mouse retinas treated as in (a) were analyzed by AngioTool. Blue dots indicate branch points. Scale
bar= 50 μm. Vertical scatter plot graph represents the average number of branch points per each field. Mean ± SEM; n= 18 in Peak1+/+; n= 30 in
Peak1+/−; n= 18 in Peak1−/−. c Phase-contrast images of resected aortic tissue embedded in matrigel from Peak1+/+, Peak1+/− or Peak1−/− mouse
aortas and treated with VEGFA at 37 °C for 6 days. Arrows point to representative vascular sprouts radiating from aortic explants. Scale bar= 300 μm.
Bar graph represents the average cumulative length of vessel sprouts per aortic ring; Mean ± SEM; n= 10. d Phase-contrast images of resected aortic
ring tissue embedded in matrigel from Peak1flox/flox mice and treated ex vivo with adenoviruses encoding either GFP (CMV-GFP) or Cre recombinase
(CMV-Cre). The aortic rings were then treated with VEGFA at 37 °C for 6 days. Scale bar= 300 μm. Arrows point to representative sprouts. Left bar
graph represents the relative indicated mRNA levels from mouse aortic rings compared to Hprt1 and normalized with CMV-Cre group. Mean ± SEM; n
= 3. Right bar graph represents the cumulative vessel length per aortic ring. Mean ± SEM; n= 10. ***P < 0.001; **P < 0.01; N.S., not significant
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Fig. 9 (See legend on next page.)
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angiogenesis by regulating VEGFR2 mRNA expression in
mouse tissues.
PEAK1 regulates VEGFA-induced angiogenesis in tumor
tissues
VEGFA/VEGFR2-dependent angiogenesis supports
tumor growth in many human cancers4. To determine if
PEAK1 regulates VEGFA-induced angiogenesis and
tumor growth, we developed a syngeneic mouse model of
breast cancer using Peak1−/− null mutant and Peak1+/+
wild type mice and the E0771 breast cancer cell line
derived from a spontaneous medullary breast adeno-
carcinoma in C57BL/6 mice with mutated p5327. We also
engineered these cells to secrete VEGFA using an ade-
novirus encoding mouse VEGFA, which drives a strong
angiogenic response characterized by increased tumor
microvascular density28. Indeed, E0771 tumors expressing
VEGFA showed significantly increased microvascular
density and tumor size in Peak1+/+ animals, compared to
tumors derived from control E0771 cells or E0771 cells
expressing GFP only. Strikingly, VEGFA-induced tumor
growth and microvascular density in Peak1−/− mice was
significantly impaired compared to Peak1+/+ mice
(Fig. 9a). These findings indicate that Peak1 expression
contributes to VEGFA-driven angiogenesis in syngeneic
mouse tumor tissues.
We next determined the vascular expression of PEAK1
in breast cancer patient tissue samples using immuno-
histochemical staining and a PEAK1-specific antibody9, 10.
PEAK1 protein was highly expressed and co-localized in
CD31-positive vessels in breast cancer tissues compared
to adjacent non-cancerous tissues (Fig. 9b). Interestingly,
blood vessels in adjacent tissue also showed PEAK1
immunoreactivity, but it was restricted to the abluminal
regions of vessels, while in breast cancer samples, it was
highly expressed on the luminal side of vessels, where it
strongly co-localized with CD31-positive ECs (Fig. 9b).
Thus, PEAK1 is highly expressed in ECs of tumor-
associated vessels, but not in CD31-positive ECs present
in adjacent normal breast tissues.
Using The Cancer Genome Atlas (TCGA) database and
bioinformatics, we examined the expression correlations
of PEAK1 mRNA and VEGFR2 mRNA levels across 32
different human cancers. We found that PEAK1 and
VEGFR2mRNA expression are highly correlated in 17 out
of 32 cancer types including invasive breast carcinoma
(Fig. 9c, d, Supplementary Table S7). Therefore, deregu-
lated expression of the PEAK1-VEGFR2 axis may con-
tribute widely to human cancers. Interestingly, GATA2
mRNA expression is not significantly correlated with
either PEAK1 or VEGFR2 mRNA in most cancer types
(Supplementary Table S7), which is consistent with our
findings that PEAK1 regulates GATA2 protein degrada-
tion at the post-translational level (Fig. 7e–h). These
findings indicate that Peak1 may play a role in VEGFA/
VEGFR2-driven human tumor growth and angiogenesis.
Discussion
In our study, we investigated the role of PEAK1 in
development and angiogenesis using biochemical, pro-
teomic, and in vitro angiogenesis assays combined with
established vertebrate animal models of neovasculariza-
tion. Using these approaches, we provide multiple lines of
evidence that a PEAK1-GATA2 transcriptional pathway
(see figure on previous page)
Fig. 9 PEAK1 regulates tumor-induced angiogenesis and correlates with VEGFR2 expression in human cancers. a Immunofluorescence
staining with antibody against CD31 (red) and DAPI (blue) of mouse syngeneic tumor sections at day 10 after injection of tumor cells. WT, original
E0771 cells; GFP AD, GFP adenovirus infected E0771 cells; VEGF AD, VEGF adenovirus infected E0771 cells. Arrows point to neo-vessels. Left bar graph
represent microvascular density in tumor sections determined by counting the number of CD31-positive vascular structures per square mm. Mean ±
SEM; n= 18. Right bar graph shows weight of excised tumors. Mean ± SEM; n= 6. b Confocal images of co-immunofluorescent labeling of CD31
(red) and PEAK1 (green) in breast cancer sections from human tissue microarray. Arrows point to the neo-vessels and stars label the tumor cells.
BRCA, breast invasive carcinoma tissue; Normal, adjacent non-cancerous tissue. Vertical scatter plot graph represents Manders’ coefficient analysis of
PEAK1 vs. CD31 colocalization. Total of 36 individual cases from tumor tissues and 6 cases from adjacent non-cancerous tissues were analyzed. For
each case, three independent fields were imaged by confocal microscope. c RNA-seq by Expectation-Maximization (RSEM) normalized RNA-seq data
of 1100 breast cancer patients from The Cancer Genome Atlas (TCGA) database were log2 transformed and calculated for the Pearson’s correlation
coefficient between PEAK1 and VEGFR2. A linear regression fit was also plotted (red line). d The heat map shows Pearson’s correlation coefficient
between PEAK1 and VEGFR2 expression from various human cancer types analyzed as in (c). The analyzed case numbers were indicated after the
abbreviation of each cancer type. ACC Adrenocortical carcinoma, BLCA Bladder Urothelial Carcinoma, BRCA Breast invasive carcinoma, CESC Cervical
squamous cell carcinoma and endocervical adenocarcinoma, CHOL Cholangiocarcinoma, COAD Colon adenocarcinoma, DLBC Lymphoid Neoplasm
Diffuse Large B-cell Lymphoma, ESCA Esophageal carcinoma, GBM Glioblastoma multiforme, HNSC Head and Neck squamous cell carcinoma, KICH
Kidney Chromophobe, KIRC Kidney renal clear cell carcinoma, KIRP Kidney renal papillary cell carcinoma, LAML Acute Myeloid Leukemia, LGG Brain
Lower Grade Glioma, LIHC Liver hepatocellular carcinoma, LUAD Lung adenocarcinoma, LUSC Lung squamous cell carcinoma, MESO Mesothelioma,
OV Ovarian serous cystadenocarcinoma, PAAD Pancreatic adenocarcinoma, PCPG Pheochromocytoma and Paraganglioma, PRAD Prostate
adenocarcinoma, READ Rectum adenocarcinoma, SARC Sarcoma, SKCM Skin Cutaneous Melanoma, TGCT Testicular Germ Cell Tumors, THCA Thyroid
carcinoma, THYM Thymoma, UCEC Uterine Corpus Endometrial Carcinoma, UCS Uterine Carcinosarcoma, UVM Uveal Melanoma. ***P < 0.001; **P <
0.01; *P < 0.05; N.S., not significant. Scale bar= 30 μm
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controls VEGFR2 transcription to drive neovasculariza-
tion in vertebrates. First, perturbation of peak1 in zebra-
fish by MOs or TALENs significantly inhibited
angiogenesis and reduced vegfr2 expression, and most
importantly, vegfr2 expression and vessel development
was restored in these animals following co-injection of
gata2a mRNA (Fig. 7c, d). Second, mechanistic studies in
ECs showed that PEAK1 binds to and controls GATA2
protein stability to regulate VEGFR2 transcription and
angiogenesis in an ECM-dependent manner. Third, MO-
mediated co-depletion of peak1 and vegfa in developing
zebrafish synergistically inhibited angiogenesis. Fourth,
development of the retinal plexus was significantly
delayed in Peak1−/− mice, which is largely driven by
Vegfa/Vegfr2 signaling29, and de novo knockout of Peak1
in mouse aorta explants robustly inhibited VEGFA-
induced new vessel formation, which was associated
with reduced VEGFR2 expression. Fifth, mouse breast
cancer cells engineered to secrete Vegfa and transplanted
into Peak1−/− null mice showed significantly impaired in
tumor growth and microvascular formation. Finally,
interrogation of human cancer databases revealed that
PEAK1 and VEGFR2 mRNA expression are highly cor-
related in many human cancers (17 of 32). Taken toge-
ther, these findings are consistent with a model in which
EC adhesion to the ECM promotes PEAK1 and GATA2
association leading to increased GATA2 protein stability.
The elevated GATA2 protein promotes expression of
VEGFR2 mRNA and protein, which in turn promotes
increased downstream signaling to effectors that drive EC
migration, proliferation, survival, and a more proangio-
genic phenotype (Supplementary Fig. S9). However, other
angiogenic factors also likely contribute to this process.
For example, the proangiogenic regulators MMP1,
ICAM1, and JAG1 were all significantly downregulated
upon PEAK1-depletion in human ECs. On the other
hand, PEAK1-depletion in HUVECs did not alter protein
expression of other tyrosine kinases including VEGFR1
and EGFR, suggesting PEAK1′s regulation of VEGFR2 is
dedicated to this receptor tyrosine kinase. We are cur-
rently investigating how PEAK1 coordinates the regula-
tion of these angiogenic factors and the role that the ECM
plays in this process.
While our findings indicate that PEAK1-GATA2 sig-
naling regulates VEGFR2 transcription in response to
ECM signals, it is likely that VEGFR2 transcription is
tightly regulated by multiple signaling networks that
impinge on nuclear transcription factors such as
GATA230, GTF2I31, NF-κB32, Sp133, HIF-1α34, HESR-135,
and Stat336. For example, changes in ECM elasticity
control nuclear localization of GATA2 to mediate
VEGFR2 transcription in ECs21. Nuclear GATA2 levels
were higher in cells attached to stiffer gels and VEGFR2
mRNA and protein were increased under these
conditions21. This response was dependent on p190Rho-
GAP signaling to mediate VEGFR2 transcriptional upre-
gulation. Our findings reveal another distinct level of
regulation of VEGFR2 transcription induced by the ECM.
We found that GATA2 protein levels are modulated by
ubiquitination and proteasome destruction in response to
EC adhesion to the ECM. PEAK1 and GATA2 were
observed to co-precipitate in ECs in response to ECM
adhesion, which suggests that PEAK1 may shield GATA2
from the ubiquitination machinery leading to increased
protein stability. This in turn could increase the effective
concentration of GATA2 available to activate VEGFR2
transcription. GATA2 is known to be ubiquitinated by E3
ubiquitin ligase SCFFBW7 (a complex of SKP1, cullin-1,
and FBW7) in HEK293 and Hela cells24, and FBW7 is
required for proper angiogenesis in mice37. Interestingly,
it appears that PEAK1-GATA2-mediated VEGFR2
expression operates independent of GTF2I and
p190RhoGAP as we did not observe changes in their
protein expression nor did we observe changes in nuclear
localization of GTF2I in response to PEAK1 signaling. It
should be noted that our studies were performed using
ECM-coated dishes which are noncompliant rigid matri-
ces, whereas the study by Mammoto and colleagues were
performed using compliant elastic gels. These findings
support the emerging idea that VEGFR2 expression is
tightly regulated by multiple pathways driven by differ-
ences in ECM elasticity and mechanosensing cues present
in the extracellular environment.
While it has been shown that PEAK1 has weak tyrosine
kinase activity in vitro7, its putative endogenous substrate
has yet to be identified. Recent evidence indicates that the
putative ATP binding site of PEAK1 is occluded in its
crystal structure38, suggesting it may act as a pseudo-
kinase in physiological conditions. Moreover, previous
studies indicates that tyrosine phosphorylation of PEAK1
depends on SRC family kinases activity7, 9, 10, 39, while we
found that SRC activity is dispensable for PEAK1′s reg-
ulation of VEGFR2 transcription in ECs (data not shown).
We have also analyzed phosphorylation sites of human
GATA2 with NetPhos 3.1 server and identified 11 puta-
tive tyrosine phosphorylation sites; however, none of these
sites have been related to the transcriptional regulation of
VEGFR2. Taken together, our results support the
hypothesis that PEAK1 acts as a scaffold protein rather
than a kinase in ECs where it interacts with GATA2, and
this interaction inhibits GATA2 ubiquitination and
increased its protein stability, which in turn increases
VEGFR2 mRNA expression.
Besides the delayed development of the retinal vascu-
lature and malocclusions in mice, we did not observe
gross defects in overall body and organ development in
peak1-null zebrafish or in Peak1−/− mice. Homozygous
Peak1−/− mice were born at expected Mendelian ratios,
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appeared normal into adulthood, were fertile, and showed
only a slightly increased incidence of malocclusions. Also,
peak1 null zebrafish embryos (homozygous peak1Δ2/ Δ2)
did not display vascular defects and survive to become
fertile adults (data not shown). These findings indicate
that Peak1 could be largely dispensable for normal
embryonic development. However, genetic compensation
due to deleterious gene mutations is likely at play in these
animals. Indeed, treatment of peak1Δ2/ Δ2 null zebrafish
embryos with peak1 specific MOs failed to induce defects
in embryogenesis and vascular formation indicating that
these animals had activated functional compensatory
mechanisms16. Genetic compensation induced by dele-
terious gene mutations, but not gene knockdown, com-
monly lead to different phenotypes as recently described
for egfl7 mutants and MO-induced morphant zebrafish16.
While the mechanisms underlying the compensation in
Peak1 mutants are likely complex, initial findings in our
laboratory indicate that Pragmin (SGK223) is an unlikely
candidate even though it is PEAK1′s closest relative and
the only other member of the NKF3 family of tyrosine
kinases6. In fact, Pragmin protein expression in Peak1−/−
MEFs and Pragmin mRNA levels in Peak1−/− mouse
tissues are not altered (data not shown). Also, PEAK1
knockdown in HUVECs did not alter Pragmin expression.
However, to fully address this issue it will be necessary to
knockout both PEAK1 and Pragmin in zebrafish and
mice.
Although Peak1 compensatory mechanisms may oper-
ate during animal development, our findings clearly
demonstrative that Peak1 plays a critical role in mediating
angiogenesis in adult organisms. Angiogenesis was
strongly impaired in aortas isolated from Peak1−/− adult
mice and tumor-induced angiogenesis was impaired in
Peak1−/− mice. Also, angiogenesis was strongly inhibited
in aortas isolated from Peak1flox/flox mice and treated with
adeno-Cre to delete the Peak1 gene. These findings
indicate that PEAK1 plays a more prominent role in adult
animals in response to stress conditions such as tissue
injury and cancer. In fact, in normal non-cancerous ves-
sels, PEAK1 expression was specifically restricted to the
outer abluminal surface of mature vessels, but not the
endothelium. These findings suggest that PEAK1 may be
up-regulated in newly forming vessels and down-
regulated during vessel maturation. It should also be
noted that PEAK1 expression is elevated in many human
cancers including breast and pancreatic9–11, 39, 40. More
interestingly, recent study suggested the treatment of an
anti-VEGFA monoclonal antibody in pancreatic ductal
adenocarcinoma lead to SRC kinase-induced phosphor-
ylation of PEAK1 in a collagen-dependent manner41.
These findings suggest a possible role of PEAK1 in
resistance to anti-VEGFA therapies, which are the main
therapies used to target tumor-induced angiogenesis in
clinic42. The fact that PEAK1 drives both tumor pro-
gression and mediates tumor-induced angiogenesis makes




All animals were treated according to the University of
California San Diego animal welfare guidelines as
described and approved by the UCSD Institutional Ani-
mal Care and Use Committee (S12005 and S06008).
Wildtype AB, transgenic Tg(fli1:egfp)y1 and Tg(fli1:nls-
egfp)y7 zebrafish were kindly provided by Dr. David Traver
(UCSD). Zebrafish were maintained as previously descri-
bed43. C57BL/6 J mice were purchased from Jackson
Laboratory. All mice were maintained in a specific
pathogen-free vivarium.
Generation of Peak1flox/flox mice and Peak1−/− mice
Peak1flox/flox mice were generated by Ingenious Target-
ing Laboratory. Briefly, targeted iTL IC1 (C57BL/6)
embryonic stem cells were microinjected into Balb/c
blastocysts, from which chimeras with a high percentage
of black coat color were crossed with C57BL/6 FLP mice
to remove the Neo cassette. Resulting heterozygous
Peak1flox/+ mice were crossed with Tg(EIIa-Cre) C57Bl/6
mice (kindly provided by Dr. Jeffrey D. Esko, UCSD) to
generate heterozygous Peak1+/− mice, which were then
in-crossed to produce the homozygous Peak1−/− straight
knockout mice. Mice were genotyped using the schematic
strategy (Supplementary Fig. S7a) with primers listed in
Supplementary Table S1.
Generation of heritable TALEN-mediated mutations in
zebrafish peak1 gene
TALEN plasmids targeting zebrafish peak1 gene were
constructed from the stock cassette as previously pub-
lished14 and the targeting site was illustrated in Supple-
mentary Fig S2b. TALEN mRNAs were synthesized with
Sp6 transcription kit (Ambion) as described in online
methods. TALEN mRNAs of the left arm (TALEN L) and
the right arm (TALEN R) were mixed at a 1:1 ratio to a
final concentration of 60 ng/μl each. A total of 1 nl of
TALEN mRNAs was injected into the one-cell stage
embryos. Genomic DNA was extracted from individual
embryo or from the tail fin of adult zebrafish and was
genotyped by PCR and MslI enzyme digestion, and con-
firmed by sequencing as previously described.14
Cell culture
Human Umbilical Vein Endothelial Cells (HUVEC,
C2517A) and Human Cardiac Microvascular Endothelial
Cells (HMVEC-C, CC7030) were purchased from Lonza
and cultured in EGM-2 medium (Lonza) on collagen I (5
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µg/cm2, Gibco, A10483) or fibronectin (1 µg/cm2, Sigma,
F1141) pre-coated plates unless otherwise indicated. Cells
obtained from Lonza were considered as passage 1, and
only cells from passage 3 to 6 were used for the experi-
ments. Cells were harvested for analysis at sub-confluent
stage. E0771 murine breast cancer cells were purchased
from CH3 Biosystems and cultured in RPMI-1640 med-
ium (Gibco) with 10% fetal bovine serum (FBS, Gibco).
Primary endothelial cells and E0771 cells were authenti-
cated by the company. All cell stocks were tested for
mycoplasma contamination by PCR and were negative.
Morpholino and microinjection
Morpholino antisense oligonucleotides (MOs) were
purchased from Gene Tools (Philomath, OR). SP1MO 5′-
GACTGAGAAAGGTAGCTTACTTCAT-3′ and SP2MO
5′- AGATCTGAGA TCAGACAAAACGGGA- 3′ were
used to block zebrafish peak1 gene, VEGFMO 5′-
GTATCAAATAAACAACCAAGTTCAT-3′ was used to
block zebrafish vegfa gene18, CtrlMO 5′-
CCTCTTACCTCAGTTACAATTTATA-3′ was used as a
control morpholino. Unless otherwise indicated, 3.2 ng
MOs were injected with 0.1% phenol red into zebrafish
embryos at the 1 cell stage.
In vitro transcription, mRNA injection and rescue
experiments
The coding region of zebrafish peak1 gene was cloned
into pCS2+ vector for zebrafish peak1 mRNA synthesis,
while pCSDest-gata2a-2A-tdTomato plasmid was kindly
provided by Dr. David Traver for zebrafish gata2a mRNA
synthesis. The mMESSAGE mMACHINE® SP6 Tran-
scription Kit (Thermo Fisher) was used to synthesize the
mRNA by in vitro transcription. After precipitation with
lithium chloride (in the kit) and washing with 70% pre-
chilled ethanol for at least 3 times, the mRNA was dried
and resuspended in RNase free water and the con-
centration was determined by Nanodrop (Thermo Fisher).
Rescue experiments were conducted by co-injection of
100 pg peak1 mRNA, gata2a mRNA or 100 pg control
RFP mRNA with 3.2 ng indicated MO into zebrafish
embryos at the 1 cell stage.
Zebrafish cell transplantation assay
Cell transplantation was performed, as described pre-
viously44. Briefly, Tg(fli1:EGFP)y1 embryos were used as
the donors and wildtype AB embryos were used as reci-
pients. At the one-cell stage, either the donor embryos or
the recipient embryos were injected with the indicated
morpholino (Supplementary Fig. S3). And phenol red was
injected into donor embryos as an indicator. At the sphere
stage, embryos were manually dechorionated. Approxi-
mately 40–60 cells from the marginal zone of a donor
embryo were transferred to the counterpart region of a
recipient embryo. The recipient embryos were then grown
at 28 °C and imaged at 32hpf. Endothelial cells (ECs) in
chimeric embryos originating from donor Tg(fli1:EGFP)y1
embryos were visualized by their green fluorescence
under the Olympus FV1000 confocal microscope. The
length of each fluorescent intersegmental vessels (ISV)
was measured using the Nikon Elements software.
SiRNAs and transfection
Predesigned siRNAs were purchased from Sigma or
Qiagen. The catalog numbers of all the siRNAs were listed
in the Supplementary Table S3. siPEAK1 is a 1:1 mixture
of siPEAK1-1 and siPEAK1-2. HUVECs, HMVECs, U87
or U87 EGFRVIII cells were transfected with indicated
siRNA using lipofectamine RNAiMAX (Invitrogen)
according to the manufacturer’s manual. The knockdown
efficiency of these siRNAs were confirmed by qPCR and
western blot. All the primers used in this study were listed
in Supplementary Table S1.
Plasmids and transfection
The plasmid pcDNA-GATA2 (#1287) and pGL3-
VEGFR2-780 (#21307) were purchased from Addgene
and amplified and purified with endotoxin free mini
plasmid prep kit (MO BIO Laboratories). The purified
plasmids were transfected into HUVECs using Lipo-
fectamine 3000 (ThermoFisher Sci) according to manu-
facturer’s protocol.
Fibrin gel angiogenic sprouting assay
Angiogenic sprouting assay was performed, as pre-
viously described45. Briefly, Cytodex 3 beads (GE health-
care) were coated with HUVECs at a concentration of 400
cells per bead at 37 °C for 4 h and then allowed for
adhesion overnight in EGM-2 medium. HUVEC-coated
beads were resuspended in 2mg/mL fibrinogen solution
(Sigma) at a concentration of 500 beads/ml. In total, 500
μl (0.625 Units/mL) of thrombin was added to each well of
a 24-well plate, then 500 μl of fibrinogen/bead suspension
was added to each well. After gels clotted, fibroblasts were
seeded on top of the gel at a concentration of 20,000 cells
per well. Beads were photographed at Day 5 with bright-
field microscopy and analyzed in the Nikon Elements
software.
Matrigel based tube formation assay
Tube formation assay was performed as described46.
Briefly, HUVECs were seeded in matrigel (growth factor
reduced basement membrane matrix, Trevigen) and
incubated with EGM-2 medium or EBM-2 medium
(Lonza) with 2% FBS and 100ng/ml VEGF (Peprotech).
Cells were incubated at 37 °C for 6 h, fixed in 4% PFA and
imaged with bright-field microscopy. Five randomized
fields were taken per each condition in each experiment.
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The cumulative length of the tubes were measured using
the Nikon Elements software.
Real time cell analysis: cell migration and proliferation
Experiments were carried out using the xCELLigence
RTCA DP instrument (ACEA Biosciences) in a humidi-
fied incubator at 37 °C and 5% CO2 according to manu-
facturer’s protocols. Cell proliferation experiments were
performed on collagen-coated 16-well E plates (ACEA
Biosciences). SiRNA transfected ECs suspended in EBM-
2+ 0.5% FBS were plated at 1500 cells/well after over-
night starvation. The impedance of each well surface,
which indicates the cell spreading area, was recorded at
15-min intervals as arbitrary units (Cell Index), and
plotted against time to generate cell proliferation curves
for a 72 h period. The proliferation slopes (Cell Index/
hour) of the curves from 3 h to 72 h after plating were
calculated using the xCELLigence software. Cell migra-
tion experiments were performed on 16-well CIM plates
(ACEA Biosciences) with both sides of the upper chamber
coated with Collagen. SiRNA transfected ECs suspended
in EBM-2+ 0.2% FBS were plated at 30,000 cells/well
after overnight starvation. The bottom chamber was loa-
ded with EBM-2+ 2%FBS with or without 30ng/ml
VEGF. The impedance of the bottom surface of the upper
chamber, which indicates the presence of the migrated
cells, was recorded at 15-min intervals as arbitrary units
(Cell Index), and plotted against time to generate cell
migration curves for a 16 h period. The migration slopes
(Cell Index/hour) of the curves from 2 to 12 h were cal-
culated by the xCELLigence software. All experiments
were done in quadruplicates.
Annexin V/7-AAD assay for apoptotic analysis of HUVECs
Briefly, HUVECs were transfected with siRNAs and
cultured in EBM-2+ 0.5% FBS medium with or without
50ng/ml VEGF for 24 h. After trypsinization, apoptotic
rate of HUVECs was measured by staining cells with FITC
Annexin V Apoptosis Detection kit with 7-AAD (Biole-
gend) followed by fluorescence-activated cell sorting
(FACS) analysis using FACSCanto (BD). Cells that were
Annexin positive and 7-AAD negative (early) or positive
(late) were designated as apoptotic. Pan Caspase inhibitor
Z-VAD-FMK (R&D system) was applied at a concentra-
tion of 100μM to block caspase-dependent apoptosis.
Quantitative proteomic analysis of HUVECs with TMT
labeling and mass spectrum
Cells were lysed in in 50mM HEPES (Sigma), pH 8.5,
containing 75 mM NaCl (Sigma), 3% sodium dodecyl
sulfate (Fisher), 1 mM sodium fluoride (Sigma), 1 mM
beta-glycerophosphate (Sigma), 1 mM sodium orthova-
nadate (Sigma), 10 mM sodium pyrophosphate (Sigma), 1
mM phenylmethylsulfonyl fluoride (Sigma) and 1 ×
Complete mini EDTA free protease inhibitors (Roche)47.
Proteins were digested in a two-step process with LysC
(Wako) and Trypsin, and then desalted with C18 Sep-
Paks (Waters) as previously described48. Samples were
labeled with 10-plex TMT reagents (Thermo Scientific) as
previously described49. Fractionation was carried out by
basic pH reverse-phase liquid chromatography with
fraction combining, as previously described48. LC-MS2/
MS3 experiments were conducted on an Orbitrap Fusion
(Thermo Fisher) with an in-line Easy-nLC 1000 (Thermo
Fisher). The Orbitrap Fusion was run in data-dependent
mode, where a survey scan was collected over 500–1200
m/z at a resolution of 120,000 in the Orbitrap. For MS2/
MS3 analysis, the decision tree option was used, with
charge state and m/z range as qualifiers. MS3 analysis was
conducted using the synchronous precursor selection
(SPS) option to maximize TMT quantitation sensitivity50.
Centroided data were collected for all MS3 scans. Resul-
tant data files were processed using Proteome Discoverer
2.1 (Thermo Fisher). MS2 data were queried against the
Uniprot Human database using the Sequest algorithm51.
Reporter ion intensities from TMT reagents were
extracted from MS3 spectra for quantitative analysis, and
signal to noise values were used for quantitation. Protein
level quantitation values were calculated by summing
signal to noise values for all peptides per protein meeting
the specified filters. Data were filtered to a 1% peptide and
protein level false discovery rate using the target-decoy
strategy52. Data were normalized in a two-step process,
whereby they were first normalized to the mean for each
protein. To account for variation in the amount of protein
labeled, values were then normalized to the median of the
entire dataset. Final values are reported as normalized
summed signal to noise per protein per sample. Gene
ontology analysis was conducted on proteins that were
significantly differentially regulated (p < 0.05, student’s t-
test, fold-change ≥ 2) between samples using the DAVID
server53, 54. All identified proteins were specified as the
background. Filters were set as previously described55.
Significant associations (Benjamini-Hochberg p < 0.05)
with a false discovery rate of less than 5% are reported.
Quantitative RT-PCR
Total RNA was extracted from cultured cells or zebra-
fish embryos with Trizol (Invitrogen) and purified with
the RNeasy RNA purification kit (Qiagen). cDNA was
synthesized with iScript cDNA synthesis kit (Bio-Rad),
and quantitative RT-PCR was performed on StepOnePlus
real time PCR system (Applied Biosystems) with SYBR
Green probes (Applied Biosystems). Human or mouse
hypoxanthine phosphoribosyltransferase 1 (HPRT1) gene
or zebrafish beta-actin1 (actb1) gene was used as an
internal reference respectively. Ratios of the expression
level of each gene to the reference gene were then
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calculated with Microsoft Excel. Primers used in this
study were listed in Supplementary Table S1.
Immunoblots and co-immunoprecipitation
ECs were cultured and treated with siRNAs or plasmids
as described above. Cells were harvested at sub-confluent
stage. For VEGF stimulation, cells were transfected with
indicated siRNA for 48 h, then starved for 12 h in EBM-2
medium with 0.5% serum, and stimulated with 50ng/ml
VEGF for 10min. For MG-132 and Chloroquine treat-
ment, 10 μM MG-132 (Sigma) and 100 μM Chloroquine
(Sigma) were used respectively to treat the HUVECs for
indicated times. Cell lysates were generated using stan-
dard methods with lysis buffer (50 mM HEPES, pH 7.4,
150mM NaCl, 1% Triton X-100, 1% sodium deox-
ycholate, 0.1% SDS, 10% glycerol, cocktail protease inhi-
bitors and phosphatase inhibitors). For co-
immunoprecipitation, cell lysates from 15 cm plates were
1:1 diluted with HNTG buffer (50 mM HEPES, pH 7.4,
150mM NaCl, cocktail protease inhibitors and phospha-
tase inhibitors). A 30 μl agarose slurry of normal mouse
IgG-AC (Santa Cruz) or mouse anti-GATA2 AC (Santa
Cruz) was added to the cell lysates respectively. For ana-
lyzing the poly-ubiquitination of GATA2, HUVECs were
cultured and treated with siRNAs as described above and
then treated with 10μM MG-132 for 6 h. Cells were then
lysed with Lysis buffer II (50 mM HEPES, pH 7.4, 150mM
NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.5%
SDS, 10% glycerol, cocktail protease inhibitors and
phosphatase inhibitors) for 30 min. A 30 μl agarose slurry
of mouse anti-GATA2 AC (Santa Cruz) was then added
to the cell lysate and incubated for 3 h. Immunoprecipi-
tated GATA2 were then washed with Lysis buffer II for
three times and boiled with sample buffer for western
blot. For immunoblots analysis, proteins were boiled in
LDS sample buffer and resolved on Nupage 4–12% gel
(Invitrogen). All the antibodies used in this study were
listed in Supplementary Table S2.
Immunofluorescence labeling of cells
HUVECs were cultured on collagen-coated coverglass
as indicated above. The cells were then transfected with
siRNAs as described above. After 48 h of transfection, the
cells were fixed with fresh 4% paraformaldehyde and
permeabilized with 0.2% triton in PBS. The cells were
then stained with indicated antibodies listed in Supple-
mentary Table S2 and DAPI, as previously described56.
Fluorescent images of 10 independent fields of each
sample were taken by Nikon Eclipse Ti epi-fluorescence
microscope and analyzed using the Image J 1.50b software
with JACOP plugin.
Luciferase reporter assay
Luciferase reporter assay was performed, as previously
described21. Briefly, plasmid pGL3-VEGFR2-780
(Addgene) was transfected into HUVECs with lipofecta-
mine 3000 (Thermo Fisher). After 12 h, siRNAs were
transfected as described above. The expression of luci-
ferase was assayed using Luciferase Assay System kit
(Promega), and the luciferase activity was measured in
duplicates in SpectraMAX Gemini EM (Molecular Devi-
ces). Four biological replicates were done for each sample
and non-transfected cells were used as blank control.
Overexpression of GFP-PEAK1 in HUVECs by lentivirus
infection
Briefly, high titer lentiviruses (10E8 plaque-forming unit
(PFU)/ml) encoding GFP-PEAK1 gene and control GFP
gene were purchased from Sirion Biotech (Germany).
Transduction was performed in cell pellet with 25 μl of
indicated virus after washing with PBS and SureEntry
reagent (1:1250, Sabiosciences). 48 h after transduction,
cells were selected with Puromycin (1 μg/mL) for 7 days.
Surviving cells were used for further experiments.
Isolation of mouse embryonic fibroblasts
Mouse fibroblasts were isolated from skin punch of
E18 week Peak1+/+ and Peak1−/− mouse embryos.
Briefly, pregnant mice were euthanized with CO2 and
cleaned with ethanol before embryos were extracted.
Embryo tissue explants were washed with sterile PBS,
containing 1% penicillin/streptomycin, transferred to the
plastic plate and covered with medium. Fibroblasts that
started to appear on the border of the tissue 5 to 7 days
later were expanded and used in experiments.
Whole mount immunofluorescent staining of the neonatal
mouse retina
Whole mount immunofluorescent staining of mouse
retina was performed as previously described57. Briefly,
retinas harvested from postnatal P7 pups and littermates
were fixed in 4% paraformaldehyde (PFA) for 10 min and
then dissected in PBS. The retinas were then permeabi-
lized in pre-chilled methanol for 10min and blocked in
PBS with 20% FBS/20% normal goat serum (NGS)+ 0.3%
Triton X-100 for 2 h. The retinas were incubated with
primary antibodies in (10% FBS/10% NGS)+ 0.3% Triton
X-100 in PBS) overnight (O/N) at 4 °C. After extensive
washing, the retinas were incubated with secondary
antibodies for another 2 h at room temperature (RT). In
Fig. 8b, c, two groups of littermates were used. All the
antibodies were listed in Supplementary Table S2.
Fluorescent image of the whole retina was taken by
Keyence BZX-700 Fluorescent Microscope and analyzed
using the Nikon Elements software. The branch points of
the vasculature from 3 independent fields from each
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retina were analyzed by the AngioTool58 downloaded
from National Cancer Institute website.
Mouse aortic ring assay
The aortic ring assay was performed, as described pre-
viously26. Thoracic aortae were isolated from 8 weeks old
Peak1−/− mice or the Peak1+/+ and Peak1+/− littermates.
Thoracic aortae were then cleaned and sliced into 0.5 mm
long rings. Or thoracic aortae were isolated from 8 weeks
old Peak1flox/flox mice and were infected with adenoviruses
(CMV) encoding either GFP or Cre recombinase (Viral
Vector Core Facility, University of Iowa Carver College of
Medicine). After overnight starvation in the Opti-MEM
medium (Invitrogen), aortic rings were placed in wells of a
48-well plate containing 65μl solidified Cultrex® Reduced
Growth Factor Basement Membrane Matrix (Trevigen)
and then covered with additional 65μl Matrigel. After
incubation at 37 °C for 30 min, each well was filled with
Opti-MEM medium supplemented with 2.5% FBS and
30ng/ml VEGFA. Rings were incubated at 37 °C for 6
days, and medium was changed every 2 days. The rings
were photographed with a Leica M165 FC stereomicro-
scope and images were analyzed using the Nikon Ele-
ments software.
Mouse syngeneic tumor model
E0771 cells were infected with mouse VEGFA adeno-
virus (Cell Biolabs) or GFP control adenovirus at multi-
plicity of 100, as previously described28. Unselected
population of virus-infected or non-infected cells (1E6
cells/100 μl) were subcutaneously injected into the bilat-
eral flanks of immunocompatible 8-week old Peak1+/+ or
Peak1−/− female mice. The mice were euthanized after
10 days, and the tumors were isolated, weighed and fixed
in 4% PFA overnight. The fixed tumors were then sent to
the histology core of the Moores Cancer Center (UCSD)
for routine paraffin embedding and sectioning.
Immunofluorescence labeling of human tumor tissue
microarrays and mouse tumor sections
Immunofluorescence labeling of human tumor tissue
was performed, as previously described59, 60. Antigen
retrieval was done with 0.5M Tris–HCl buffer (pH 10) for
10min in a pre-heated pressure cooker (Nordic Ware).
Antibodies were diluted in TBS buffer with 5% NGS and
1% BSA. All the antibodies were listed in Supplementary
Table S2. Sections were incubated overnight at 4 °C with
primary antibodies. After extensive washing, sections
were then incubated for 2 h at RT with fluorescently
labeled secondary antibodies. Negative controls were
conducted with the particular isotype controls. Human
breast cancer tissue microarrays were purchased from US
Biomax (BR8014 and BR243). Stained sections were
imaged in Olympus FV1000 confocal microscope and
analyzed using the ImageJ 1.50b software with JACOP
plugin.
Pearson’s correlation coefficient analysis of mRNA
expression in cancer patients
RSEM61 normalized RNA-seq data of 9283 TCGA
patients spanning 32 different cancer types were down-
loaded from Firehose (https://confluence.broadinstitute.
org/display/GDAC/Home) on Aug 21, 2015. We then log2
transformed the RNA-seq data and calculated the Pear-
son’s correlation coefficient between the mRNA expres-
sion of PEAK1 and VEGFR2 in each cancer type. A linear
regression fit was plotted and overlaid with scatter plot for
visualization.
Data availability
All data are available within the article and its Supple-
mentary Information files or from the corresponding
author upon reasonable request.
Statistical analysis
Sample size of mouse syngeneic model was estimated by
using statistical power (biomath http://www.biomath.
info/power/ttest.htm). Briefly, with a sample size of 6
tumors, significant differences of 30% can be detected
with 80% power at a 0.05 significance level, assuming a
standard deviation within groups of 0.15. GraphPad
Prism5 were used to perform the statistical analysis
(GraphPad software). The data distribution was assumed
to be normal, although we did not formally test it. Results
are presented as Mean ± SEM. Statistical significance was
determined by two-tailed Student’s t test, One-way or
Two-way ANOVA with Bonferroni post-test respectively.
***P < 0.001; **P < 0.01; *P < 0.05; (N.S.), not significant.
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